Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Dec 31;18(1):1-10.
doi: 10.1080/21645515.2021.1885278. Epub 2021 May 6.

Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study

Indraneel Basu  1 , Manish Agarwal  2 , Viral Shah  3 , Vijay Shukla  4 , Sunil Naik  5 , Pravin Dinkar Supe  6 , Manoj Kumar Srivastava  7 , Kanakapura Vrushabaiah Giriraja  8 , Peersab Pinjar  9 , Pradeep Kumar Mishra  10 , Shishir Joshi  11 , Ranjit Vijayakumar  12 , Serge van de Witte  13
Affiliations
Clinical Trial

Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India - A phase III, active-controlled, randomized clinical study

Indraneel Basu et al. Hum Vaccin Immunother. .

Abstract

Background: This study was conducted to compare the immunogenicity and safety profile of two quadrivalent influenza vaccines (QIVs) in healthy adults (18-60 years) and elderly (>61 years) participants.

Method: This phase III study was conducted from March 2018 to April 2018 across 12 sites in India. In this randomized, observer-blind, active-controlled study, 480 participants were randomized to receive a single dose of test vaccine (subunit, inactivated influenza vaccine; Influvac® Tetra, Abbott) (n = 240) or reference vaccine (split virion, inactivated influenza vaccine; VaxiFlu-4, Zydus Cadilla Healthcare) (n = 240). The primary objective was to describe and compare the immunogenicity of each vaccination group based on hemagglutination inhibition (HI) assay seroprotection and seroconversion rates, and geometric mean fold increase (GMFI) against four vaccine strains in two age groups. Safety and reactogenicity were also compared for the vaccines in both the age groups.

Results: The pre- and post-vaccination HI titers for both the vaccines were comparable. The GMFI varied from 4.3 - 22.7 in the test and 3.7-21.6 in the reference vaccine group. The seroprotection rates were >90% for the A-strains and ranged between >43% and <60% for B-strains for both the vaccines. Seroconversion rates varied between 41.4% and 78.8%. Overall, the reported adverse events (AEs) for both the vaccines were <1% and comparable. Reported local and systemic reactions were comparable.

Conclusion: Influvac® Tetra elicited an adequate immune response with a favorable safety profile which was comparable with the reference vaccine. (Clinical trial registry number: CTRI/2018/02/012222).

Keywords: Immunogenicity; immunosenescence; quadrivalent influenza vaccine; reactogenicity; safety.

PubMed Disclaimer

Conflict of interest statement

Serge van de Witte is an employee of Abbott Healthcare Products B.V. All other authors were the investigators in the study and received grant support from Abbott to conduct this study. No other conflict of interest is declared for the work presented in this article.

Figures

Figure 1.
Figure 1.
Participant disposition.
Figure 2.
Figure 2.
Reverse cumulative distribution (RCD) curves.
See this image and copyright information in PMC

References

    1. Immunization Action Coalition . 2020. [Accessed 2020 Feb 6th]; https://www.immunize.org/catg.d/p4208.pdf
    1. WHO Influenza (Seasonal) . 2020 [Accessed 2021 Feb 15]; https://www.who.int/en/news-room/fact-sheets/detail/influenza-(seasonal)
    1. Centers for Disease Control and Prevention 2020 [Accessed 2021 Feb 15]; https://www.cdc.gov/flu/vaccines-work/vaccineeffect.htm
    1. National Institute of allergy and Infectious Diseases . 2020. [Accessed 2020 Mar 4]; https://www.niaid.nih.gov/diseases-conditions/influenza-diagnosis
    1. CDC Antiviral Drugs . 2020 [Accessed 2021 Feb 15]; https://www.cdc.gov/flu/treatment/whatyoushould.htm

Publication types

LinkOut - more resources